Oncolytics Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ONCY and other ETFs, options, and stocks.

About ONCY

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. 

CEO
Jared Kelly
CEOJared Kelly
Employees
29
Employees29
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
29
Employees29

ONCY Key Statistics

Market cap
47.28M
Market cap47.28M
Price-Earnings ratio
-1.36
Price-Earnings ratio-1.36
Dividend yield
—
Dividend yield—
Average volume
1.09M
Average volume1.09M
High today
$0.3866
High today$0.3866
Low today
$0.3363
Low today$0.3363
Open price
$0.3834
Open price$0.3834
Volume
1.26M
Volume1.26M
52 Week high
$1.30
52 Week high$1.30
52 Week low
$0.3363
52 Week low$0.3363

Stock Snapshot

The current Oncolytics Biotech(ONCY) stock price is $0.36, with a market capitalization of 47.28M. The stock trades at a price-to-earnings (P/E) ratio of -1.36.

On 2026-11-14, Oncolytics Biotech(ONCY) stock traded between a low of $0.34 and a high of $0.39. Shares are currently priced at $0.36, which is +8.1% above the low and -5.9% below the high.

Oncolytics Biotech(ONCY) shares are trading with a volume of 1.26M, against a daily average of 1.09M.

In the last year, Oncolytics Biotech(ONCY) shares hit a 52-week high of $1.30 and a 52-week low of $0.34.

In the last year, Oncolytics Biotech(ONCY) shares hit a 52-week high of $1.30 and a 52-week low of $0.34.

ONCY News

TipRanks 2d
Oncolytics Biotech Enters Clinical Supply Agreement with Coherus

Oncolytics Biotech ( (ONCY) ) has issued an update. On November 11, 2026, Oncolytics Biotech announced it had entered a clinical supply agreement with Coherus...

TipRanks 2d
Patrick Trucchio Maintains Buy Rating and Unchanged $5 Price Target as Coherus Agreement Revives Pelareorep’s Development Path

Oncolytics Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy...

People also own

Based on the portfolios of people who own ONCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.